TILODENE ticlopidine hydrochloride 250mg tablet bottle

Երկիր: Ավստրալիա

Լեզու: անգլերեն

Աղբյուրը: Department of Health (Therapeutic Goods Administration)

Ակտիվ բաղադրիչ:

ticlopidine hydrochloride

Հասանելի է:

Alphapharm Pty Ltd

Լիազորման կարգավիճակը:

Registered

Տեղեկատվական թերթիկ

TILODENE
1
TILODENE
_contains the active ingredient ticlopidine hydrochloride_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Tilodene.
It does not contain all of the
available information. It does not
take the place of talking to your
doctor or pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Tilodene against
the benefits they expect it will have
for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
Keep this leaflet with your medicine.
You may need to read it again.
WHAT TILODENE IS USED
FOR
Tilodene is used to help prevent the
formation of blood clots.
Tilodene belongs to a group of
medicines called 'platelet aggregation
inhibitors'. These medicines work by
reducing the ability of blood clotting
cells (platelets) to stick to each other
and to blood vessel walls. This
lessens the ability of blood clots
forming in unwanted places such as
narrowed blood vessels.
Tilodene is used in patients who are
at risk of having a stroke. A stroke
occurs when a blood clot blocks a
blood vessel in the brain.
Tilodene is used in patients who
cannot take aspirin or in whom
aspirin does not work.
Your doctor may have prescribed
Tilodene for another reason. Ask
your doctor if you have any
questions about why Tilodene has
been prescribed for you.
Tilodene is not recommended for use
in children, as there have been no
studies of its effects in children.
Tilodene is available only with a
octor's prescription.
BEFORE YOU TAKE
TILODENE
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE TILODENE IF YOU ARE
ALLERGIC TO TICLOPIDINE
HYDROCHLORIDE OR ANY OF THE
INGREDIENTS LISTED AT THE END OF THIS
LEAFLET.
DO NOT TAKE TILODENE IF YOU ARE
OVER 65 YEARS OF AGE AND HAVE LIVER
OR KIDNEY PROBLEMS.
DO NOT TAKE TILODENE IF YOU HAVE
ANY OF THE FOLLOWING MEDICAL
CONDITIONS:
*
any blood disorder such as a low
white blood cell count, no white
blood cells or a low platelet count
*
any active bleeding problems
such as

Ապրանքի հատկությունները

TILODENE
_Ticlopidine hydrochloride_
PRODUCT INFORMATION
NAME OF THE MEDICINE
Active ingredient: Ticlopidine hydrochloride
Chemical name: 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno-(3,2-c)
pyridine hydrochloride (IU PAC)
The structural formula for ticlopidine hydrochloride is:
N
S
Cl
,HCl
Molecular formula: C
14
H
14
ClNS.HCl
Molecular weight: 300.2
CAS Registry No.: 53885-35-1
DESCRIPTION
Ticlopidine hydrochloride is a white crystalline solid, which is
slightly soluble in acetone and sparingly soluble
in water, ethanol, methylene chloride, and buffer solutions above pH
6.0. An aqueous solution of ticlopidine has
a pH of 3.6. Each Tilodene tablet contains 250 mg of ticlopidine
hydrochloride. The tablets also contain
cellulose - microcrystalline, povidone, starch - maize, ammonium
chloride, stearic acid, magnesium stearate and
Opadry II White Y-30-18037.
PHARMACOLOGY
_MECHANISM OF ACTION._
Ticlopidine is an inhibitor of platelet aggregation. When taken orally
it causes a time and
dose dependent inhibition of platelet aggregation and release of
platelet factors, as well as a prolongation of
bleeding time. The drug has no significant
_in vitro_
activity. The exact mechanism of action is not fully
characterised, but does not involve inhibition of the
prostacyclin/thromboxane pathways. Platelet cyclic AMP
(adenosine monophosphate) does not see m to play a role in the
mechanism of action of ticlopidine. Ticlopidine
interferes with platelet membrane function by inhibiting ADP
(adenosine diphosphate) induced platelet-
fibrinogen binding and subsequent platelet-platelet interactions.
The effect of ticlopidine on platelet function is irreversible as
shown both by inhibition of fibrinogen binding
after washing and by inhibition of platelet aggregation after
resuspension of platelets in buffered medium.
Although it is unclear how ticlopidine brings about these changes, a
suggested mechanism is that it inhibits ADP
induced exposure of the fibrinogen binding site of the glycoprotein
IIb-IIIa complex.
PHARMACODYNAMICS
Inhibiti